A Master Batch Record Is Not an Executed Batch Record

Three identities on one commercial packet

Quality and contract-manufacturing teams often collapse three distinct Current Good Manufacturing Practice documentation identities into one colloquial packet called the batch record. A signed 21 CFR 211.186 master production and control record is not a 21 CFR 211.188 executed batch production and control record, and neither is 21 CFR 211.192 quality-control-unit production-record review.

For one commercial drug-product packet, mark each identity present, missing, or unknown. Do not treat a signed master as proof that a named batch was executed, or an executed batch record as 211.192 review and release:

• The Master Production and Control Record (21 CFR 211.186): An independently checked, dual-signed template for each drug product, including each batch size. Required contents include name and strength, dosage-form description, active-ingredient weights, a complete component list, theoretical yield including the min/max percentages that trigger 211.192, container-closure and labeling specimens, and complete manufacturing and control instructions.

• The Batch Production and Control Record (21 CFR 211.188): An accurate reproduction of the approved master, issued for a specific commercial lot and populated with contemporaneous evidence demonstrating that each significant processing, packaging, and testing step was accomplished at the time of performance pursuant to 21 CFR 211.100(b).

• The Production Record Review and Investigation (21 CFR 211.192): Documented quality-control-unit review and approval of all production and control records, including packaging and labeling, to determine compliance with established approved written procedures before a batch is released or distributed. Unexplained discrepancies shall be thoroughly investigated. Approve-or-reject authority, including for products made under contract, is 21 CFR 211.22; 211.192 review is not 211.165 laboratory determination.

This page is not the Stage 2 process-validation worksheet comparing protocol execution to finished-product testing (A PPQ Protocol Is Not Commercial Batch Release); it is not the analytical laboratory worksheet differentiating out-of-specification test results from field alert reporting (An OOS Result Is Not Confirmed Failure or a Field Alert); it is not the retrospective review worksheet distinguishing annual evaluations from continued process verification (An Annual Product Review Is Not Continued Process Verification); nor is it a second-site technology transfer encyclopedia (Tech-transfer package gaps before moving a commercial product to a second site) or an eCTD regulatory supplement guide (eCTD Module 3 lifecycle hygiene after multiple post-approval supplements).

This page does not invent discrepancy rates, yield-failure rates, review clocks, or search demand. The governing text is Title 21 of the Code of Federal Regulations, with Federal Register notices, FDA guidance (nonbinding except where it cites statute or regulation), and warning letters as enforcement evidence. A dated sample of actual master and executed records was not reviewed.

flowchart TD
    subgraph Master["21 CFR 211.186 identity"]
        M1["Each drug product, including each batch size"]
        M2["Dual signatures or documented 11.2(a) equivalents"]
        M3["Theoretical yield min/max that trigger 211.192"]
    end
    subgraph Execution["21 CFR 211.188 identity"]
        E1["Accurate reproduction of the appropriate master"]
        E2["Significant-step documentation at time of performance"]
        E3["211.188(b)(12) attachment is not 211.192 review"]
    end
    subgraph Review["21 CFR 211.192 identity"]
        R1["QC-unit review of all production and control records before release"]
        R2["Investigate unexplained discrepancies, including yield outside master limits"]
        R3["211.165 laboratory determination is a labeled boundary"]
    end

What 21 CFR 211.186 actually requires

21 CFR 211.186, displayed on eCFR with Title 21 last amended 11 September 2026, is titled Master production and control records. The section remains the 29 September 1978 text (43 FR 45077) with no later amendment note on the section itself. Industry captions Master Batch Record, MBR, MPR, and Master Production Record are inspection and industry shorthand for this template identity, not a fourth legal document type.

Under 21 CFR 211.186(a), to assure uniformity from batch to batch, master production and control records for each drug product, including each batch size thereof, shall be prepared, dated, and signed (full signature, handwritten) by one person and independently checked, dated, and signed by a second person. The preparation of master production and control records shall be described in a written procedure and such written procedure shall be followed. A master written for one batch size is not the 211.186 template for a different batch size.

Paragraph (b) of 211.186 establishes nine mandatory content elements that every master production and control record must contain:

1. Name, strength, and dosage form: The name and strength of the product and a description of the dosage form (211.186(b)(1)).

2. Active-ingredient weight or measure: The name and weight or measure of each active ingredient per dosage unit or per unit of weight or measure of the drug product, and a statement of the total weight or measure of any dosage unit (211.186(b)(2)).

3. Complete component list: A complete list of components designated by names or codes sufficiently specific to indicate any special quality characteristic (211.186(b)(3)). The Code does not enumerate particle-size or polymorph fields; those details matter only if they are the special quality characteristic the name or code must indicate.

4. Component weights and justified variations: An accurate statement of the weight or measure of each component, using the same weight system for each component. Reasonable variations in the amount of components necessary for the dosage form are permitted if they are justified in the master (211.186(b)(4)). A justified variation on the master is not an unexplained 211.192 discrepancy.

5. Calculated excess: A statement concerning any calculated excess of component (211.186(b)(5)).

6. Theoretical in-process weight or measure: A statement of theoretical weight or measure at appropriate phases of processing (211.186(b)(6)).

7. Theoretical yield and 211.192 trip limits: A statement of theoretical yield, including the maximum and minimum percentages of theoretical yield beyond which investigation according to 211.192 is required (211.186(b)(7)). Under 21 CFR 210.3(b)(17), theoretical yield is the quantity that would be produced at a phase based on the quantity of components to be used, in the absence of any loss or error. Those percentages are trip limits on the template; they are not documentation that a named batch was made.

8. Containers, closures, and labeling specimens: A description of the drug product containers, closures, and packaging materials, including a specimen or copy of each label and all other labeling signed and dated by the person or persons responsible for approval of such labeling (211.186(b)(8)). That specimen approval is not 211.134 finishing-operations examination and is not 211.192 review of the whole packet.

9. Manufacturing and control instructions: Complete manufacturing and control instructions, sampling and testing procedures, specifications, special notations, and precautions to be followed (211.186(b)(9)). Those contents remain a template. They are not documentation that each significant step was accomplished for a named batch.

What 21 CFR 211.188 adds once a named batch is made

While 21 CFR 211.186 is the template, 21 CFR 211.188, titled Batch production and control records, requires that batch production and control records shall be prepared for each batch of drug product produced and shall include complete information relating to the production and control of each batch.

Under 21 CFR 211.188(a) the executed record shall include an accurate reproduction of the appropriate master production or control record, checked for accuracy, dated, and signed. That issued reproduction is a different identity from the master it copies. A signed 211.186 master sitting in the packet, even if issued as the blank form for a future batch, is not 211.188 documentation that each significant step was accomplished.

211.188(b) then requires documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished, including:

1. Dates: Dates (211.188(b)(1)). The Code does not require start-and-stop clocks for every operation as a separate caption; it requires dates as part of documenting that each significant step was accomplished.

2. Major equipment and lines: Identity of individual major equipment and lines used (211.188(b)(2)). Serial numbers and asset tags are one way to identify equipment; they are not additional legal document types.

3. Component and in-process batches: Specific identification of each batch of component or in-process material used (211.188(b)(3)).

4. Weights and measures used: Weights and measures of components used in the course of processing (211.188(b)(4)). Scale-calibration logs are not a substitute for this field, and they are not themselves a 211.186 master.

5. In-process and laboratory control results: In-process and laboratory control results (211.188(b)(5)). Those copied results are not 21 CFR 211.194 laboratory records as a separate identity, and they are not 211.165 laboratory determination prior to release.

6. Packaging and labeling area inspection: Inspection of the packaging and labeling area before and after use (211.188(b)(6)).

7. Actual yield and percentage of theoretical: A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing (211.188(b)(7)). Under 21 CFR 210.3(b)(18)–(19) and 21 CFR 211.103, actual yield and percentage of theoretical shall be determined at the conclusion of each appropriate phase, calculated by one person and independently verified by a second person, or independently verified by one person if calculated by automated equipment under 211.68. Crossing the master's min/max is a 211.192 investigation trigger, not proof that QC-unit review has already occurred.

8. Labeling control records: Complete labeling control records, including specimens or copies of all labeling used (211.188(b)(8)). Label-quantity reconciliation is industry practice; the Code's required caption here is complete labeling control records including specimens or copies.

9. Containers and closures used: Description of drug product containers and closures (211.188(b)(9)).

10. Sampling performed: Any sampling performed (211.188(b)(10)).

11. Persons performing and checking, including automated steps: Identification of the persons performing and directly supervising or checking each significant step, or, if a significant step is performed by automated equipment under 211.68, the identification of the person checking that automated step (211.188(b)(11)). 211.188(b)(11) was revised at 73 FR 51933 (8 September 2008). 211.68(c) allows automated equipment used for operations addressed by 211.101(c) or (d), 211.103, 211.182, or 211.188(b)(11) to satisfy one-person-performs and second-person-checks requirements if the equipment is used in conformity with 211.68 and one person checks that the equipment properly performed the operation.

12. Any 211.192 investigation: Any investigation made according to 211.192 (211.188(b)(12)). An investigation document can sit inside the executed packet. That attachment is not quality-control-unit review and approval of all production records before release.

13. 211.134 examination results: Results of examinations made in accordance with 211.134 (211.188(b)(13)). 211.134 requires packaged and labeled products to be examined during finishing operations, a representative sample of units to be visually examined for correct labeling at completion of finishing operations, and those results to be recorded in the batch production or control records. Those results are not 211.186(b)(8) labeling-specimen approval and are not 211.192 review of the whole packet.

The contemporaneous-execution hook that 211.188(b) needs is 21 CFR 211.100(b): written production and process-control procedures shall be followed in the execution of the various production and process-control functions and shall be documented at the time of performance. Any deviation from the written procedures shall be recorded and justified. Pre-filling initials and dates without documentation of performance is the LiquidCapsule pattern cited under 211.188. Completing 211.100(a) procedure approval, or signing a 211.186 master, does not document a significant step at the time of performance for a named batch.

211.192 review is a third identity

Even when a batch record is filled with contemporaneous signatures and attachments, that executed booklet is still a 211.188 identity. Under 21 CFR 211.192, titled Production record review, all drug-product production and control records, including those for packaging and labeling, shall be reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed.

211.192 is a third identity. Completing an executed record, even with an attached 211.188(b)(12) investigation, does not itself perform that review. The quality control unit's review is directed at whether the records show compliance with established, approved written procedures, including:

• Approved-procedure compliance: Whether production, packaging, and labeling records show that written production and process-control procedures were followed (211.192; 211.100).

• Record completeness for the named batch: Whether the 211.188 reproduction and significant-step fields are present so the quality control unit can review them. Health Pharma and LiquidCapsule show that missing executed fields and missing quality-unit review of executed records can be cited as separate failures; they are not this packet.

• Yield against the master limits: Whether actual yield and percentage of theoretical at appropriate phases sit inside the 211.186(b)(7) min/max. Crossing those limits is an unexplained discrepancy that shall be thoroughly investigated, whether or not the batch has already been distributed.

211.192 states that any unexplained discrepancy—specifically including any percentage of theoretical yield exceeding the master limits—or the failure of a batch or any of its components to meet specifications, shall be thoroughly investigated, whether or not the batch has already been distributed. The investigation shall extend to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy. A written record of the investigation shall be made and shall include the conclusions and followup. The Code writes followup as one word. It does not set investigation clocks or typical discrepancy rates.

Attaching an investigation under 211.188(b)(12) does not perform 211.192 review and approval before release. 21 CFR 211.22(a) gives the quality control unit authority to review production records to assure that no errors have occurred or that they have been fully investigated, and to approve or reject drug products, including those manufactured under contract. 211.22(c) assigns approval or rejection of procedures and specifications impacting identity, strength, quality, and purity. 211.22(d) requires those responsibilities and procedures to be in writing and followed.

Production-record review is not laboratory determination under 21 CFR 211.165. 211.165(a) still requires, for each batch of drug product, an appropriate laboratory determination of satisfactory conformance to final specifications, including identity and strength of each active ingredient, prior to release. Completing a 211.186 master or a 211.188 executed record does not perform that determination. The published PPQ-versus-commercial-release worksheet already owns Stage 2 versus 211.165 commercial lot release; this page only labels 211.165 as a boundary, not a fourth worksheet field. Health Pharma separately cited 211.22 for shipping before adequate quality-unit review. LiquidCapsule's distributed batch with an incomplete QA checklist sits inside the 211.188 citation, which is why executed-record completeness and review-before-release must stay separate fields even when FDA places them in one letter.

Electronic signatures, EBR systems, and CDMO packets

Electronic masters and electronic batch records remain 211.186 and 211.188 identities. Part 11 is a trustworthiness overlay. It does not merge them and does not perform 211.192 review.

A common misreading is that 21 CFR 211.186(a)'s parenthetical (full signature, handwritten) forbids electronic masters. FDA's December 2018 guidance Data Integrity and Compliance With Drug CGMP: Questions and Answers (docket FDA-2018-D-3984; HTML landing page still marked content current as of 13 December 2018) is nonbinding except where it cites statute or regulation. Question 11 asks whether electronic signatures can be used instead of handwritten signatures for master production and control records. The answer is yes: electronic signatures with the appropriate controls can be used instead of handwritten signatures or initials in any CGMP required record. Although 211.186(a) specifies a full signature, handwritten, an electronic signature with the appropriate controls to securely link the signature with the associated record fulfills this requirement (21 CFR 11.2(a)). Firms using electronic signatures should document the controls used to identify the specific person who signed electronically. Under 21 CFR 11.1(c), electronic signatures that meet part 11 are equivalent to full handwritten signatures, initials, and other general signings unless specifically excepted by a regulation effective on or after 20 August 1997. 211.186 is not such an exception. There is no handwritten-signature requirement for the master production and control record in the PET CGMP regulations (21 CFR part 212); that overlay is not this finished-drug worksheet.

Question 9 of the same guidance states that electronic copies can be used as true copies of paper or electronic records, provided the copies preserve the content and meaning of the original record, including metadata required to reconstruct the CGMP activity. 21 CFR 211.180(d) permits retention as original records or as true copies such as photocopies, microfilm, microfiche, or other accurate reproductions. Retention of an executed packet is not 211.192 review, and retaining a master is not proof a named batch was made. Under 21 CFR 211.68(b), appropriate controls shall be exercised over computer or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel, and that input to and output from the computer of formulas or other records or data shall be checked for accuracy. A single electronic system can hold both identities; the worksheet still has to mark which identity the packet currently is.

An electronic master is still a 211.186 template. An electronic batch record is still a 211.188 identity. Closing a batch in software without documented quality-control-unit review does not perform 211.192. Part 11 does not create a third record type.

In contract manufacturing, a quality agreement may allocate who authors the 211.186 master, who executes the 211.188 record, and who transmits the packet for 211.192 review. FDA's November 2016 guidance Contract Manufacturing Arrangements for Drugs: Quality Agreements (docket FDA-2013-D-0558; HTML landing page still marked content current as of 7 May 2020) is nonbinding except where it cites statute or 21 CFR. It states that a quality agreement cannot exempt owners or contract facilities from statutory or regulatory responsibilities to comply with applicable CGMP.

Labeled boundaries: PPQ, APR, EU Chapter 4, and ICH Q7

Keep this three-record finished-drug worksheet apart from adjacent identities:

• Stage 1 process design vs. this commercial packet: FDA's January 2011 guidance Process Validation: General Principles and Practices (announced at 76 FR 4360, 25 January 2011; HTML landing page still marked content current as of 24 August 2018) is nonbinding except where it cites statute or regulation. It states that CGMP documents for commercial manufacturing, including the initial commercial master batch production and control record (211.186) and supporting procedures, are key outputs of Stage 1, process design. Establishing that Stage 1 master is not 211.188 execution of a later commercial lot, and it is not 211.192 review of that lot. Stage 2 PPQ versus concurrent release versus 211.165 commercial release versus Stage 3 CPV remains A PPQ Protocol Is Not Commercial Batch Release: Stage 2 Versus Stage 3 Records.

• 211.180(e) annual evaluation vs. lot review: Under 21 CFR 211.180(e), written records required by part 211 shall be maintained so that data therein can be used for evaluating, at least annually, the quality standards of each drug product to determine the need for changes in drug product specifications or manufacturing or control procedures. Written procedures shall be established and followed for those evaluations, including a review of a representative number of batches, whether approved or rejected, and a review of complaints, recalls, returned or salvaged drug products, and investigations conducted under 211.192. That at-least-annual evaluation identity is owned by An Annual Product Review Is Not Continued Process Verification. Completing 211.192 on a named lot is not the annual evaluation, and completing the annual evaluation is not 211.192 review of a named lot.

• EU Chapter 4 documentation split: EU GMP Part I Chapter 4 (Documentation, January 2011) is a labeled boundary, not this US worksheet. Paragraphs 4.17 and 4.18 require approved written Manufacturing Formula and Processing Instructions for each product and batch size. Paragraph 4.20 requires a Batch Processing Record for each batch processed. Paragraph 4.21 requires a separate Batch Packaging Record for each batch or part batch processed. US 21 CFR 211.188 includes packaging, labeling, and 211.134 examination results inside one batch production and control record, with 211.192 then reviewing those records including packaging and labeling. Annex 16 QP certification is a different legal role from the US quality control unit and is not this page.

• ICH Q7 API overlay: FDA's September 2016 Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients is the API overlay, not finished-drug 21 CFR 211. It is nonbinding in the US except where it cites statute or regulation. Section 6.40 says master production instructions for each intermediate and API should be prepared, dated, and signed by one person and independently checked, dated, and signed by a person in the quality unit(s). Section 6.50 says batch production records should be an accurate reproduction of the appropriate master. Sections 6.70 and 6.71 address review and approval of batch production and laboratory control records before API release, including a narrower delegation for noncritical process steps. That API split does not rewrite 211.192 for finished pharmaceuticals, which requires quality-control-unit review of all drug-product production and control records before release.

• Device history records: A device history record under 21 CFR 820 / the Quality Management System Regulation is a different publication's reader job, not this finished-drug worksheet.

One fictional packet: present, missing, or unknown

The following worksheet marks a clearly labeled hypothetical commercial drug-product packet. Interior master files, executed batch records, and quality-control-unit review tickets were not reviewed, so several rows stay Unknown. Present and Missing rows are identity states in the hypothetical packet, not findings about a real site, and they are not lot-specific release, rejection, or investigation-closure advice.

When marking one commercial packet, keep these identity tests separate:

1. A signed master is not proof a named batch was made: 211.186 is a template identity, including theoretical-yield limits that trigger 211.192. Purolea shows that an AI-generated master used without 211.22(c) review is still a master-identity failure, not an executed batch.

2. An executed record is not 211.192 review: Health Pharma shows missing executed-step documentation and missing quality-unit review of executed records cited separately. LiquidCapsule shows pre-filled initials, missing contemporaneous in-process results, and distribution with an incomplete QA checklist inside a 211.188 citation. Those letters are not typical-rate evidence.

3. Yield outside master min/max is an investigation trigger, not a typical rate: 211.192 requires a thorough investigation of that unexplained discrepancy, whether or not the batch has already been distributed, extending to other batches and associated products. This page does not invent yield-failure rates or close an investigation for a named lot.

4. Owner 211.22 is not moved by a quality-agreement signature: Case 2 of the 2016 quality-agreement guidance treats an executed record that matches the agreement but not the actual process as a CGMP failure. Allocation of drafting or transmission is not identity merger.

5. Adjacent manufacturing jobs stay on their own pages: Stage 2 PPQ versus 211.165 versus Stage 3 is A PPQ Protocol Is Not Commercial Batch Release. One laboratory result is An OOS Result Is Not Confirmed Failure or a Field Alert. 211.180(e) versus Stage 3 is An Annual Product Review Is Not Continued Process Verification. Second-site packages, Module 3 lifecycle operators, inspection clocks, Type V DMFs, sterile RFQs, method-transfer criteria, CMC-only CRLs, ICH Q12 established conditions, recall triage, and warning-letter volume remain Tech-transfer package gaps before moving a commercial product to a second site, eCTD Module 3 lifecycle hygiene after multiple post-approval supplements, PAI readiness for a launch-critical facility when approval timing is tight, PreCheck's Type V Facility DMF Is Not a PAI, and a CDMO Seat Does Not Transfer CGMP, Annex 1 CCS Is Not FDA's 2026 Packaging CCS, and Neither Replaces 2004 Aseptic Guidance, Analytical Method Transfer Acceptance Criteria for a New Release-Testing Lab, CMC-only complete response letters: how commercial teams should read the risk, ICH Q12 established conditions in regulatory submissions, FDA drug recall lookup: reading a Class I/II/III notice and pharmacy triage, and FDA Warning Letters by the Numbers (2026): CDER Drug Enforcement Surge.

Sources

• 21 CFR 211.186 — Master production and control records (eCFR: Title 21 last amended 11 September 2026; 43 FR 45077, 29 September 1978).

• 21 CFR 211.188 — Batch production and control records (eCFR: Title 21 last amended 11 September 2026; amended at 73 FR 51933, 8 September 2008).

• 21 CFR 211.192 — Production record review (eCFR: Title 21 last amended 11 September 2026; 43 FR 45077, 29 September 1978).

• 21 CFR 211.100 — Written procedures; deviations (eCFR: Title 21 last amended 11 September 2026).

• 21 CFR 211.22 — Responsibilities of quality control unit (eCFR: Title 21 last amended 11 September 2026).

• 21 CFR 211.165 — Testing and release for distribution (eCFR: Title 21 last amended 11 September 2026).

• 21 CFR 211.134 — Drug product inspection (eCFR: Title 21 last amended 11 September 2026).

• 21 CFR 211.180 — General requirements (records, retention, and true copies) (eCFR: Title 21 last amended 11 September 2026).

• 21 CFR 211.68 — Automatic, mechanical, and electronic equipment (eCFR: Title 21 last amended 11 September 2026; amended at 73 FR 51932, 8 September 2008).

• 21 CFR 211.103 — Calculation of yield (eCFR: Title 21 last amended 11 September 2026; amended at 73 FR 51932, 8 September 2008).

• 21 CFR 210.3 — Definitions (batch, theoretical yield, actual yield, percentage of theoretical yield) (eCFR: Title 21 last amended 11 September 2026).

• 21 CFR 11.1 — Electronic records; electronic signatures; scope (eCFR: Title 21 last amended 11 September 2026).

• 21 CFR 11.2 — Implementation (electronic records and signatures) (eCFR: Title 21 last amended 11 September 2026).

• FDA Guidance for Industry: Process Validation — General Principles and Practices (January 2011) (CDER/CBER/CVM, Revision 1; availability announced at 76 FR 4360, 25 January 2011, Docket FDA-2008-D-0559).

• Federal Register Notice: Guidance for Industry on Process Validation; Availability (76 FR 4360) (25 January 2011, FR Doc. 2011-1437).

• Process Validation: General Principles and Practices — FDA guidance landing page (January 2011 guidance; HTML page still marked content current as of 24 August 2018 at access).

• Data Integrity and Compliance With Drug CGMP: Questions and Answers — FDA guidance landing page (December 2018 Q&A; HTML page still marked content current as of 13 December 2018 at access).

• Contract Manufacturing Arrangements for Drugs: Quality Agreements — FDA guidance landing page (November 2016 guidance; HTML page still marked content current as of 7 May 2020 at access).

• FDA Guidance for Industry: Data Integrity and Compliance With Drug CGMP — Questions and Answers (December 2018) (CDER/CBER/CVM, Docket FDA-2018-D-3984).

• FDA Guidance for Industry: Contract Manufacturing Arrangements for Drugs — Quality Agreements (November 2016) (CDER/CBER/CVM/ORA, Docket FDA-2013-D-0558).

• Federal Register Final Rule: Amendments to Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals (73 FR 51932) (8 September 2008, FR Doc. E8-20709).

• EudraLex Volume 4, Part I, Chapter 4: Documentation (January 2011) (European Commission Guidelines for Good Manufacturing Practice for Medicinal Products).

• FDA Guidance for Industry: Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients (September 2016) (ICH Q7, CDER/CBER).

• FDA Warning Letter: Health Pharma USA LLC (MARCS-CMS 588155, 18 December 2019) (Citing 21 CFR 211.188 batch-record omissions and 21 CFR 211.22 quality-unit release failures).

• FDA Warning Letter: LiquidCapsule Manufacturing, LLC (MARCS-CMS 717069, 19 December 2025) (Citing 21 CFR 211.188 pre-filled initials and distribution prior to QA review checklist completion).

• FDA Warning Letter: Purolea Cosmetics Lab (MARCS-CMS 722591, Warning Letter 320-26-58, 2 April 2026) (Citing 21 CFR 211.22(c) for AI-generated master production and control records used without quality unit review).